<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384850</url>
  </required_header>
  <id_info>
    <org_study_id>SENTINEL</org_study_id>
    <nct_id>NCT02384850</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>SENTINEL</acronym>
  <official_title>An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GSO Global Clinical Research BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GSO Global Clinical Research BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the combination treatment of established chemotherapy regimen
      mFOLFOX6 with Selinexor, an oral Selective Inhibitor Of Nuclear Export, in patients with
      metastatic Colorectal Cancer. The purpose is to determine the maximum tolerated dose (MTD) of
      selinexor in combination with mFOLFOX6.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 9, 2017</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose</measure>
    <time_frame>28 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients experiencing adverse events</measure>
    <time_frame>treatment start to up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Selinexor + mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.</description>
    <arm_group_label>Selinexor + mFOLFOX6</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle</description>
    <arm_group_label>Selinexor + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3</description>
    <arm_group_label>Selinexor + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle</description>
    <arm_group_label>Selinexor + mFOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed diagnosis of colorectal cancer presenting with
             unresectable stage IV (UICC) disease (primary tumor may be present)

          2. Patients who are feasible for treatment with FOLFOX (prior adjuvant or palliative
             treatment is allowed)

          3. ECOG Performance status ≤ 1

          4. Life expectancy &gt; 3 months

          5. Age ≥18 years

          6. Haematologic function as follows (5% deviation allowed):

               -  ANC ≥ 1.5 x 109/L

               -  platelets ≥ 100 x109/L

               -  hemoglobin ≥ 9 g/dl or 5.59 mmol/l

          7. Adequate liver function as follows (10% deviation allowed)

               -  serum alanine transaminase (ALT) ≤ 2.5 x ULN (in case of liver metastases &lt; 5 x
                  ULN)

               -  total bilirubin ≤ 1.5 x ULN (patients with Gilbert's syndrome total bilirubin
                  ≤2.5 x ULN)

          8. Adequate renal function as follows (10% deviation allowed)

             · creatinine ≤ 1.5 x ULN

          9. Signed written informed consent

         10. Women of child-bearing potential must have a negative pregnancy test

        Exclusion Criteria:

        adequately controlled with appropriate therapy or would compromise the patient's ability to
        tolerate this therapy; 2. Treatment with any systemic anticancer therapy ≤ 3 weeks prior to
        cycle 1 day 1 3. Uncontrolled active infection (Hepatitis B and C infection are NOT
        exclusion criteria) and/or known HIV infection; 4. Renal failure requiring haemodialysis or
        peritoneal dialysis; 5. Patients who are pregnant or breast-feeding; 6. Patients with
        significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled
        vomiting or diarrhea resulting in inability to swallow oral medications; 7. Presence of
        symptomatic CNS metastasis 8. Unresolved toxicity from previous anti-cancer therapy or
        incomplete recovery from surgery, in particular oxaliplatin-induced peripheral neuropathy &gt;
        grade 1.

        9. Any of the following within the 12 months prior to study drug administration: myocardial
        infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic
        congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary
        embolism, deep vein thrombosis, or other thromboembolic event.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Bokemeyer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

